Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Dec;39(12):1205-1212.
doi: 10.1007/s40261-019-00856-8.

Evaluation of the Feasibility of a Web-Based Survey to Assess Patient-Reported Symptom Improvement and Treatment Satisfaction Among Patients with Psoriatic Arthritis Receiving Secukinumab

Marina Magrey  1 , Michael Bozyczko  2 , Daniel Wolin  3 , Margaret Mordin  3 , Lori McLeod  3 , Eric Davenport  3 , Costel Chirila  3 , Peter Hur  4
Affiliations

Evaluation of the Feasibility of a Web-Based Survey to Assess Patient-Reported Symptom Improvement and Treatment Satisfaction Among Patients with Psoriatic Arthritis Receiving Secukinumab

Marina Magrey et al. Clin Drug Investig. 2019 Dec.

Abstract

Background and objective: Patient perspectives regarding treatment experience and satisfaction may be useful for clinicians when making treatment strategies. This US-based study assessed the feasibility of evaluating real-world, patient-reported narratives regarding symptom improvement and treatment satisfaction among patients with psoriatic arthritis treated with secukinumab.

Methods: A cross-sectional, web-based survey collected data on demographics, disease characteristics, symptoms before and after secukinumab use, and treatment satisfaction with secukinumab.

Results: Of 2755 patients screened, 200 patients with psoriatic arthritis were eligible and included in the analysis. Their mean age was 36.0 (standard deviation, 10.0) years; 55.5% were male and 75.0% were white. Most (87.5%) were biologic experienced; the primary reason for discontinuation of their previous treatment was lack of effectiveness (28.6%). Most patients (79.9%) reported overall psoriatic arthritis symptom improvement after secukinumab initiation compared with before secukinumab initiation; a similar trend was observed for all individual symptoms evaluated. Approximately half of patients reported improvement within 4 weeks after starting secukinumab treatment, and > 90% reported improvement within 6 months. Most patients (≥ 96%) expressed overall satisfaction with secukinumab regarding symptom improvement, speed of symptom improvement, frequency of administration, method of administration, ease of use, patient support services, and side effects, if any.

Conclusions: Patient-reported perspectives may be feasibly collected to provide insights into treatment experience and satisfaction of secukinumab. Most patients with psoriatic arthritis in our real-world study experienced symptom improvement after initiating secukinumab; > 50% of patients reported symptom improvement within 4 weeks. Additionally, almost all patients reported satisfaction with secukinumab treatment.

PubMed Disclaimer

Conflict of interest statement

Marina Magrey has served as a consultant for Novartis. Michael Bozyczko has no conflicts of interest that are directly relevant to the content of this article. Daniel Wolin, Margaret Mordin, Lori McLeod, Eric Davenport, and Costel Chirila are employees of RTI Health Solutions. Peter Hur is an employee of Novartis.

Figures

Fig. 1
Fig. 1
Proportion of patients experiencing psoriatic arthritis symptoms before and after initiating secukinumab in a the overall population (N = 200), b patients with 3–6 months of secukinumab use (n = 89), and c patients with ≥ 7 months of secukinumab use (n = 111)
Fig. 2
Fig. 2
Patient-reported time to first noticeable improvements in psoriatic arthritis (PsA) symptoms since secukinumab initiation (N = 200)
Fig. 3
Fig. 3
Overall treatment satisfaction with secukinumab for psoriatic arthritis (PsA) [N = 200]
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Gladman DD, Antoni C, Mease P, et al. Psoriatic arthritis: epidemiology, clinical features, course, and outcome. Ann Rheum Dis. 2005;64:14–17. - PMC - PubMed
    1. Gelfand JM, Gladman DD, Mease PJ, et al. Epidemiology of psoriatic arthritis in the population of the United States. J Am Acad Dermatol. 2005;53:573. doi: 10.1016/j.jaad.2005.03.046. - DOI - PubMed
    1. Mease PJ, Gladman DD, Papp KA, et al. Prevalence of rheumatologist-diagnosed psoriatic arthritis in patients with psoriasis in European/North American dermatology clinics. J Am Acad Dermatol. 2013;69:729–735. doi: 10.1016/j.jaad.2013.07.023. - DOI - PubMed
    1. Gladman DD. Clinical features and diagnostic considerations in psoriatic arthritis. Rheum Dis Clin N Am. 2015;41:569–579. doi: 10.1016/j.rdc.2015.07.003. - DOI - PubMed
    1. Huynh D, Kavanaugh A. Psoriatic arthritis: current therapy and future approaches. Rheumatology (Oxford). 2015;54:20–28. doi: 10.1093/rheumatology/keu237. - DOI - PubMed

Publication types

Substances